BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3076 related articles for article (PubMed ID: 30653341)

  • 1. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
    Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
    Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
    Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
    Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.
    De A; Duseja A
    J Clin Exp Hepatol; 2020; 10(3):255-262. PubMed ID: 32405182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis.
    Coilly A; Desterke C; Guettier C; Samuel D; Chiappini F
    Sci Rep; 2019 Dec; 9(1):19785. PubMed ID: 31874999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic differences in intra-abdominal adipose tissue in extremely obese adolescents with different stages of NAFLD.
    Sheldon RD; Kanosky KM; Wells KD; Miles L; Perfield JW; Xanthakos S; Inge TH; Rector RS
    Physiol Genomics; 2016 Dec; 48(12):897-911. PubMed ID: 27764764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease.
    du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S
    Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic drivers of non-alcoholic fatty liver disease.
    Bence KK; Birnbaum MJ
    Mol Metab; 2021 Aug; 50():101143. PubMed ID: 33346069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.
    Crespo M; Lappe S; Feldstein AE; Alkhouri N
    Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
    Hall Z; Bond NJ; Ashmore T; Sanders F; Ament Z; Wang X; Murray AJ; Bellafante E; Virtue S; Vidal-Puig A; Allison M; Davies SE; Koulman A; Vacca M; Griffin JL
    Hepatology; 2017 Apr; 65(4):1165-1180. PubMed ID: 27863448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
    Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
    Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.
    Del Chierico F; Nobili V; Vernocchi P; Russo A; De Stefanis C; Gnani D; Furlanello C; Zandonà A; Paci P; Capuani G; Dallapiccola B; Miccheli A; Alisi A; Putignani L
    Hepatology; 2017 Feb; 65(2):451-464. PubMed ID: 27028797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 154.